News
Novo Nordisk Inks A Major Obesity Deal
Digest more
The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Cisco Systems (NASDAQ: CSCO) stock rose 0.4% ahead of the technology equipment firm’s latest results, with the company having ...
Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback